公开(公告)号：US09213032B2

公开(公告)日：2015-12-15

申请号：US13949041

申请日：2013-07-23

Applicant: SAMSUNG ELECTRONICS CO., LTD.

Inventor： Ji Min Lee ,  Kyung Ah Kim ,  Bo Gyou Kim

IPC: G01N33/53 ,  G01N33/574 ,  C12Q1/68 ,  C07K16/30 ,  C07K16/28 ,  A61K39/00

CPC classification number: G01N33/57492 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57496 ,  G01N2800/52

Abstract: A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions.

Abstract translation: 一种鉴定适合用抗c-Met抗体或其抗原结合片段治疗的细胞样品或受试者的方法，所述抗c-Met抗体或其抗原结合片段特异性结合c-Met蛋白质的SEMA结构域中的表位，通过确定c-Met蛋白中存在LRIG1 来自受试者的细胞样品，以及相关方法和组合物。

公开(公告)号：US20150212077A1

公开(公告)日：2015-07-30

申请号：US14604361

申请日：2015-01-23

Applicant: Samsung Electronics Co., Ltd.

Inventor： Bo Gyou Kim ,  Eunjin Lee ,  Kyung Ah Kim ,  Tae Jin Ahn

IPC: G01N33/53 ,  C12Q1/68 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30

CPC classification number: C12Q1/6876 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/3023 ,  C07K16/3046 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/47 ,  G01N2800/52 ,  A61K2300/00

Abstract: A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject.

Abstract translation: 使用TFF1预测c-Met抑制剂的效果和/或选择使用c-Met抑制剂的受试者的方法，使用TFF1监测c-Met抑制剂的作用的方法，以及治疗和/ 包括给所选受试者施用c-Met抑制剂。

公开(公告)号：US10246507B2

公开(公告)日：2019-04-02

申请号：US14869636

申请日：2015-09-29

Applicant: Samsung Electronics Co., Ltd.

Inventor： Seung Hyun Lee ,  Soo Yeon Jung ,  Bo Gyou Kim ,  Seung Ja Oh ,  Ji Min Lee

IPC: A61K39/395 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30

Abstract: A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.

公开(公告)号：US09192666B2

公开(公告)日：2015-11-24

申请号：US14242684

申请日：2014-04-01

Applicant: Samsung Electronics Co., Ltd.

Inventor： Bo Gyou Kim ,  Ji Min Lee ,  Kyung Ah Kim ,  Yun Ju Jeong

IPC: A61K39/395 ,  C07K16/30 ,  C07K16/28 ,  A61K31/506 ,  A61K31/519 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K31/506 ,  A61K31/519 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00 ,  A61K2300/00

Abstract: Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein.

Abstract translation: 本发明提供一种预防或治疗癌症的方法，其包括将（a）FGFR抑制剂和（b）抗c-Met抗体或其抗原结合片段共同给予有需要的受试者，其中， c-Met抗体或其抗原结合片段特异性结合到c-Met蛋白的SEMA结构域内包含5个或更多个连续氨基酸的表位。

公开(公告)号：US10578621B2

公开(公告)日：2020-03-03

申请号：US14814165

申请日：2015-07-30

Applicant: Samsung Electronics Co., Ltd.

Inventor： Ji Min Lee ,  Bo Gyou Kim ,  Kyung Ah Kim ,  Seung Ja Oh

IPC: G01N33/574 ,  C07K16/30

Abstract: A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.

公开(公告)号：US20160053025A1

公开(公告)日：2016-02-25

申请号：US14835376

申请日：2015-08-25

Applicant: Samsung Electronics Co., Ltd.

Inventor： Seungja Oh ,  Kyung Ah Kim ,  Bo Gyou Kim ,  Seung Hyun Lee ,  Ji Min Lee

IPC: C07K16/40 ,  A61K39/395 ,  A61K38/18 ,  C07K16/22

CPC classification number: A61K38/18 ,  A61K38/1891 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  A61K2300/00

Abstract: An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.

Abstract translation: 一种抗c-Met /抗Ang2双特异性抗体，包括（a）抗c-Met抗体或其抗原结合片段和（b）抗Ang2抗体或其抗原结合片段，药物组合物包括 抗c-Met /抗Ang2双特异性抗体，以及使用抗c-Met /抗Ang2双特异性抗体的方法。

公开(公告)号：US20160033518A1

公开(公告)日：2016-02-04

申请号：US14814165

申请日：2015-07-30

Applicant: Samsung Electronics Co., Ltd.

Inventor： Ji Min Lee ,  Bo Gyou Kim ,  Kyung Ah Kim ,  Seung Ja Oh

IPC: G01N33/574 ,  C07K16/30 ,  C07K16/40

CPC classification number: G01N33/57496 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  G01N2333/91205

Abstract: A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.

Abstract translation: 用于预测靶向c-Met和EGFR的双靶向药物的功效的生物标志物PNCK和预测靶向c-Met和EGFR的双靶向药物的作用的方法，选择受试者应用 靶向c-Met和EGFR的双重靶向剂，或监测靶向c-Met和EGFR的双重靶向剂的作用，包括测量PNCK和/或PNCK编码基因的水平。

公开(公告)号：US09567641B2

公开(公告)日：2017-02-14

申请号：US14323642

申请日：2014-07-03

Applicant: SAMSUNG ELECTRONICS CO., LTD. ,  GEORGETOWN UNIVERSITY

Inventor： Bo Gyou Kim ,  Shangzi Wang ,  Ji Min Lee ,  Kyung Ah Kim ,  Louis M. Weiner

IPC: A61K39/395 ,  C12Q1/68 ,  A61K45/06 ,  A61K38/18 ,  G01N33/50 ,  C07K16/28 ,  A61K38/08 ,  A61K38/10 ,  A61K38/17

CPC classification number: C12Q1/6886 ,  A61K38/08 ,  A61K38/10 ,  A61K38/1774 ,  A61K38/1808 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/2836 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/5023 ,  G01N2800/52 ,  A61K2300/00

Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.

Abstract translation: 用于与抗c-Met抗体组合治疗的靶物质，用于预防和/或治疗癌症的组合用药物组合物，包括抗c-Met抗体和针对所述靶物质的抑制剂作为活性成分的方法 用于预防和/或治疗癌症，包括共同施用抗c-Met抗体和针对靶物质的抑制剂，以及使用目标物质筛选用于预防和/或治疗癌症的药物的方法。

公开(公告)号：US20160144028A1

公开(公告)日：2016-05-26

申请号：US14949303

申请日：2015-11-23

Applicant: Samsung Electronics Co., Ltd.

Inventor： Jimin Lee ,  Bo Gyou Kim ,  Seungja Oh ,  Kyung Ah Kim ,  Powei Lin ,  Saet Byoul Lee

IPC: A61K39/395 ,  G01N33/574 ,  A61K31/4985

CPC classification number: A61K39/39558 ,  A61K31/00 ,  A61K31/4985 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  G01N33/57492 ,  G01N33/74 ,  G01N2333/65 ,  G01N2800/52

Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor

Abstract translation: 一种预防和/或治疗癌症的方法，所述方法包括将c-Met和EGFR双重抑制剂（以下称为“c-Met / EGFR双重抑制剂”）和IGF-1R抑制剂共同给予需要的受试者 并且使用IGF-1R作为对c-Met / EGFR双重抑制剂的抗性的标记物

公开(公告)号：US09233155B2

公开(公告)日：2016-01-12

申请号：US14242638

申请日：2014-04-01

Applicant: Samsung Electronics Co., Ltd.

Inventor： Bo Gyou Kim ,  Ji Min Lee ,  Kyung Ah Kim ,  Yun Ju Jeong

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/4412 ,  A61K39/00

CPC classification number: A61K39/39558 ,  A61K31/4412 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92 ,  A61K2300/00

Abstract: Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment.

Abstract translation: 本发明提供了一种预防或治疗癌症的组合疗法，包括或主要由对象给予索拉非尼和抗c-Met抗体或其抗原结合片段。 联合治疗方法可以达到优异的协同效应，降低抗c-Met抗体的有效剂量，从而实现更有效的癌症治疗。